HWG Holdings’s Bio-Rad Laboratories Class A BIO Stock Holding History

HWG Holdings’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$2K	–	148
2021 Q4	$2K	Buy	+3	New	+$2.25K	﹤0.01%	119

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HWG Holdings's BIO Position: Q1 2022 in Review

HWG Holdings sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 3 shares — an estimated $2K sold.

HWG Holdings first reported a position in BIO in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 515 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

HWG Holdings reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
HWG Holdings sold 3 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $2K.
HWG Holdings first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 1 quarter.
HWG Holdings's Bio-Rad Laboratories Class A position peaked at $2K in Q4 2021.
515 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on HWG Holdings's 13F filing for Q1 2022, filed 26 Apr 2022.